ライフサイエンスコーパス: Rous sarcoma

1 cytes, with proteins that negatively control Rous sarcoma oncogene cellular homolog (Src) activity.

2 at Y951 facilitates binding of VEGFR2 to the Rous sarcoma (Src) homology 2-domain of T cell-specific

3 totally unrelated late domain sequences from Rous sarcoma virus (contained in its p2b sequence) or eq

4 is virus integrase and bacterial recombinant Rous sarcoma virus (Prague A strain) integrase (approxim

5 resolution of a fragment of the integrase of Rous sarcoma virus (residues 49-286) containing both the

6 In particular, although both Rous sarcoma virus (RSV) and AMV could replicate in cult

7 ze budding of virus-like particles (VLPs) of Rous sarcoma virus (RSV) and HIV type 1 (HIV-1).

8 membrane binding, we fused the MA domains of Rous sarcoma virus (RSV) and HIV-1 to the chemically ind

9 the Gag protein; however, recent studies of Rous sarcoma virus (RSV) and human immunodeficiency viru

10 The Gag proteins of Rous sarcoma virus (RSV) and human immunodeficiency viru

11 The Gag proteins of Rous sarcoma virus (RSV) and human immunodeficiency viru

12 Rous sarcoma virus (RSV) and murine leukemia virus (MLV)

13 Rous sarcoma virus (RSV) and murine leukemia virus (MLV)

14 immunodeficiency virus type 1 (HIV-1) and of Rous sarcoma virus (RSV) are morphologically distinct wh

15 ssed this question using the alpharetrovirus Rous sarcoma virus (RSV) as a model system.

16 onducted to investigate the initial steps of Rous sarcoma virus (RSV) assembly by examining the assoc

17 Rous sarcoma virus (RSV) budding requires an interaction

18 The first few residues of the Rous sarcoma virus (RSV) CA protein comprise a structura

19 of charged residues in the FL region of the Rous sarcoma virus (RSV) CA to particle assembly.

20 d-state NMR (ssNMR) resonance assignments of Rous sarcoma virus (RSV) CA, assembled into hexamer tube

21 sembly incompetent by testing the ability of Rous sarcoma virus (RSV) CA-SP to assemble in vitro into

22 variety of specimens assembled in vitro from Rous sarcoma virus (RSV) CA.

23 The Gag protein of Rous sarcoma virus (RSV) can direct particle assembly an

24 structure of the N-terminal domain (NTD) of Rous sarcoma virus (RSV) capsid protein (CA), with an up

25 During virion maturation, the Rous sarcoma virus (RSV) capsid protein is cleaved from

26 an immunodeficiency virus type 1 (HIV-1) and Rous sarcoma virus (RSV) capsid proteins form a beta-hai

27 The cellular receptor for subgroup A Rous sarcoma virus (RSV) contains a single LDL-A module

28 ence appears to be modular, as the unrelated Rous sarcoma virus (RSV) Env can be made Vpu sensitive b

29 We have previously described a mutant Rous sarcoma virus (RSV) Env protein, Env-mu26, with an

30 this model, CA proteins from both HIV-1 and Rous sarcoma virus (RSV) form similar hexagonal lattices

31 We have identified an assembly-defective Rous sarcoma virus (RSV) Gag mutant that retains signifi

32 tudy in vitro-assembled, immature virus-like Rous sarcoma virus (RSV) Gag particles and have determin

33 triphosphate [PI(3,4,5)P(3)] levels impaired Rous sarcoma virus (RSV) Gag PM localization.

34 The p2 region of the Rous sarcoma virus (RSV) Gag polyprotein contains an ass

35 Nucleocytoplasmic shuttling of the Rous sarcoma virus (RSV) Gag polyprotein is an integral

36 The Rous sarcoma virus (RSV) Gag polyprotein undergoes trans

37 The Rous sarcoma virus (RSV) Gag precursor polyprotein is th

38 Proteolytic processing of the Rous sarcoma virus (RSV) Gag precursor was altered in vi

39 of the NC domain in assembly of VLPs from a Rous sarcoma virus (RSV) Gag protein and have characteri

40 We have purified Rous sarcoma virus (RSV) Gag protein and in parallel sev

41 The first 86 residues of the Rous sarcoma virus (RSV) Gag protein form a membrane-bin

42 ously reported that nuclear transport of the Rous sarcoma virus (RSV) Gag protein is intrinsic to the

43 med spontaneously in vitro from fragments of Rous sarcoma virus (RSV) Gag protein purified after expr

44 ped three very small, modular regions of the Rous sarcoma virus (RSV) Gag protein that are necessary

45 We discovered that the Rous sarcoma virus (RSV) Gag protein transiently localiz

46 In the Rous sarcoma virus (RSV) Gag protein, the 25 amino-acid

47 In the Rous sarcoma virus (RSV) Gag protein, the M domain is co

48 een these two hypotheses, we made use of the Rous sarcoma virus (RSV) Gag protein, the PR of RSV IS i

49 erminal 100 residues of the non-myristylated Rous sarcoma virus (RSV) Gag protein.

50 We used Rous sarcoma virus (RSV) Gag together with membrane sens

51 eption was the 11-amino-acid p2b sequence of Rous sarcoma virus (RSV) Gag, which could fully restore

52 essential steps in understanding the chicken Rous sarcoma virus (RSV) genome association with a nonpe

53 elatively short, 82 nucleotide region of the Rous sarcoma virus (RSV) genome, called muPsi, was shown

54 The major late domain of Rous sarcoma virus (RSV) has been mapped to a PPPY motif

55 The L domain of Rous sarcoma virus (RSV) has been shown to interact with

56 t, the L domains of oncoretroviruses such as Rous sarcoma virus (RSV) have a more N-terminal location

57 We produced kinetically stabilized Rous sarcoma virus (RSV) intasomes with human immunodefi

58 Site-directed mutagenesis of recombinant Rous sarcoma virus (RSV) integrase (IN) allowed us to ga

59 nhanced when the serine at amino acid 124 of Rous sarcoma virus (RSV) integrase is replaced by alanin

60 The Rous sarcoma virus (RSV) is an exception, in that its ge

61 About one-third of the MA protein in Rous sarcoma virus (RSV) is phosphorylated.

62 we have examined whether the alpharetrovirus Rous sarcoma virus (RSV) is susceptible to inhibition by

63 proteins that specifically interact with the Rous sarcoma virus (RSV) L domain in vitro and in vivo.

64 The discovery of Rous sarcoma virus (RSV) led to the identification of ce

65 taining the ts gene under the control of the Rous sarcoma virus (RSV) long terminal repeat (LTR) and

66 dogenous AAV promoters, p5 and p40, with the Rous sarcoma virus (RSV) long terminal repeat (LTR) and

67 eracts with the Schmidt-Ruppin strain of the Rous sarcoma virus (RSV) long terminal repeat (LTR) betw

68 The Rous sarcoma virus (RSV) long terminal repeat (LTR) cont

69 The Rous sarcoma virus (RSV) long terminal repeat (LTR) cont

70 CC-3' present on the noncoding strand of the Rous sarcoma virus (RSV) long terminal repeat (LTR) in a

71 eceptor (ecoR) cDNA under the control of the Rous sarcoma virus (RSV) long terminal repeat (LTR) prom

72 alovirus (CMV) immediate-early promoter, the Rous sarcoma virus (RSV) long terminal repeat, and the a

73 ts within the avian leukosis virus (ALV) and Rous sarcoma virus (RSV) LTR enhancers in a pattern iden

74 ssociation of HIV-1 Gag, as well as purified Rous sarcoma virus (RSV) MA and Gag, depends strongly on

75 in vitro flotation assay to directly measure Rous sarcoma virus (RSV) MA-membrane interaction in the

76 rted repeat (IR) within the U5 region of the Rous sarcoma virus (RSV) mRNA forms a structure composed

77 In this report, a Rous sarcoma virus (RSV) mutant having two acidic-to-bas

78 The Rous sarcoma virus (RSV) negative regulator of splicing

79 135-nucleotide (nt) direct repeats flank the Rous sarcoma virus (RSV) oncogene src and are composed o

80 virus-based vector LNCX, contain an internal Rous sarcoma virus (RSV) or cytomegalovirus (CMV) promot

81 ctivity compared with strong but nonspecific rous sarcoma virus (RSV) or cytomegalovirus promoters.

82 The late assembly domain (L-domain) of Rous sarcoma virus (RSV) or human immunodeficiency virus

83 virus (EIAV) is functionally homologous with Rous sarcoma virus (RSV) p2b and human immunodeficiency

84 ent of Gag in in vivo and in vitro assembled Rous sarcoma virus (RSV) particles and to compare these

85 However, in the presence of budding HIV-1 or Rous sarcoma virus (RSV) particles, some glycoproteins,

86 The Rous sarcoma virus (RSV) polyadenylation site (PAS) is v

87 mmunodeficiency virus type 1 (HIV-1) PTAP or Rous sarcoma virus (RSV) PPPY L domain in the p9 protein

88 t the enzymatic and structural properties of Rous sarcoma virus (RSV) PR are exquisitely sensitive to

89 pHyde gene under the control of a truncated Rous sarcoma virus (RSV) promoter (AdRSVpHyde) was gener

90 he cDNA for human iNOS was cloned behind the Rous sarcoma virus (RSV) promoter to create adenovirus (

91 Rous sarcoma virus (RSV) promoter-driven expression of t

92 novirus containing the HERG gene driven by a Rous sarcoma virus (RSV) promoter.

93 ontrol of the human cytomegalovirus (CMV) or Rous sarcoma virus (RSV) promoters.

94 enzyme, resulting in a highly active mutant Rous sarcoma virus (RSV) protease that displays many cha

95 ld be initiated by electroporation of cloned Rous sarcoma virus (RSV) proviral DNA into the developin

96 Expression of the Gag-Pol polyprotein of Rous sarcoma virus (RSV) requires a -1 ribosomal framesh

97 Rous sarcoma virus (RSV) requires large amounts of unspl

98 We asked whether a single Rous sarcoma virus (RSV) RNA can be translated and subse

99 The 5' untranslated region of Rous sarcoma virus (RSV) RNA is a highly ordered structu

100 inding site in the 5' untranslated region of Rous sarcoma virus (RSV) RNA play an integral role in mu

101 ing element in the 3' untranslated region of Rous sarcoma virus (RSV) RNA was found to promote Rev-in

102 We previously identified the Rous sarcoma virus (RSV) stability element (RSE), an RNA

103 a mouse monoclonal antibody directed against Rous sarcoma virus (RSV) subgroup A Env that will be use

104 produce milligram quantities of the soluble Rous sarcoma virus (RSV) synaptic complex that is kineti

105 describes new mutations in the CA protein of Rous sarcoma virus (RSV) that were designed to test whet

106 In chick embryo fibroblasts transformed by Rous sarcoma virus (RSV) the tyrosine phosphorylation of

107 V), feline immunodeficiency virus (FIV), and Rous sarcoma virus (RSV) to critically address the role

108 The Rous sarcoma virus (RSV) transmembrane (TM) glycoprotein

109 ne transport, the multidomain Gag protein of Rous sarcoma virus (RSV) undergoes importin-mediated nuc

110 RNA(Lys3) as the replication primer, whereas Rous sarcoma virus (RSV) uses tRNA(Trp).

111 discovery from Ray Erikson's group that the Rous sarcoma virus (RSV) v-Src-transforming protein had

112 ol vector containing a constitutively active Rous sarcoma virus (RSV) viral promoter driving the luci

113 A PPPPY motif within the L domain of Rous sarcoma virus (RSV) was previously characterized as

114 y reactions with purified CA proteins of the Rous sarcoma virus (RSV) were used to define factors tha

115 We previously reported that a mutant Rous sarcoma virus (RSV) with an alternate polypurine tr

116 Rous sarcoma virus (RSV), a simple retrovirus, needs to

117 resembles the PPPPY motif in the L domain of Rous sarcoma virus (RSV), an avian retrovirus.

118 HIV-1, Moloney murine leukemia virus (MLV), Rous sarcoma virus (RSV), and human T-cell lymphotropic

119 human immunodeficiency virus type 1 (HIV-1), Rous sarcoma virus (RSV), and Mason-Pfizer monkey virus

120 articles of the prototypic avian retrovirus, Rous sarcoma virus (RSV), by using scanning transmission

121 In some orthoretroviruses, including Rous Sarcoma Virus (RSV), CA carries a short and hydroph

122 ton Rous recovered a virus, now known as the Rous sarcoma virus (RSV), from a chicken sarcoma, which

123 For Rous sarcoma virus (RSV), Gag proteins are synthesized i

124 osed based on the existence of MA mutants in Rous sarcoma virus (RSV), murine leukemia virus, human i

125 During assembly and morphogenesis of Rous sarcoma virus (RSV), proteolytic processing of the

126 For Rous sarcoma virus (RSV), the size determinant maps to t

127 In the case of Rous sarcoma virus (RSV), the size determinant maps to t

128 , a Gammaretrovirus, and the Alpharetrovirus Rous sarcoma virus (RSV), were susceptible to inhibition

129 eplication-competent shuttle vector based on Rous sarcoma virus (RSV), with alternate retroviral PPTs

130 the utility of the system, we developed new Rous sarcoma virus (RSV)-based replication-incompetent v

131 tween the PBS and the CA dinucleotide of the Rous sarcoma virus (RSV)-derived vector RSVP(A)Z to matc

132 the endogenous polypurine tract (PPT) of the Rous sarcoma virus (RSV)-derived vector RSVP(A)Z was rep

133 ions in the 5' end of the U3 sequence of the Rous sarcoma virus (RSV)-derived vector RSVP(A)Z.

134 stablishment of the transformed phenotype in Rous sarcoma virus (RSV)-infected cells.

135 eplication-defective adenoviral vectors [Adv.Rous sarcoma virus (RSV)-nf] representing three families

136 vector encoding a peptide inhibitor of PKA [Rous sarcoma virus (RSV)-protein kinase A inhibitor (PKI

137 Rous sarcoma virus (RSV)-tk bearing the HSV1-tk gene wer

138 the robustly induced enzymatic activities in Rous sarcoma virus (RSV)-transformed chicken cells.

139 tures found in osteoclasts, macrophages, and Rous sarcoma virus (RSV)-transformed fibroblasts.

140 ng a well-established retroviral model-avian Rous sarcoma virus (RSV)-we analyzed changes in an RSV v

141 icken embryo fibroblasts (CEF) infected with Rous sarcoma virus (RSV).

142 odel retroviral envelope protein (EnvA) from Rous sarcoma virus (RSV).

143 +)-ATPase (SERCA2a) under the control of the Rous sarcoma virus (RSV).

144 ric interactions between the Gag proteins of Rous sarcoma virus (RSV).

145 ansforming viral oncogene product encoded by Rous sarcoma virus (RSV).

146 d CRM1-dependent nuclear cycling was that of Rous sarcoma virus (RSV).

147 -membrane interaction of the alpharetrovirus Rous sarcoma virus (RSV).

148 ecades of study on an avian RNA tumor virus, Rous sarcoma virus (RSV).

149 iruses containing the cellular receptors for Rous sarcoma virus (Tva) or ecotropic murine leukemia vi

150 One mechanism by which Rous sarcoma virus achieves incomplete splicing involves

151 chicken embryo fibroblasts (CEF) infected by Rous sarcoma virus against a confluent background of uni

152 roviruses that undergo type C morphogenesis, Rous sarcoma virus and human immunodeficiency virus, whi

153 n the SU and TM envelope protein subunits of Rous sarcoma virus and murine leukemia virus.

154 s containing TATA and/or initiator elements, Rous sarcoma virus and thymidine kinase promoters in BeW

155 peat (DR) sequences flanking the src gene in Rous sarcoma virus are essential posttranscriptional con

156 e experiments reported here, using the avian Rous sarcoma virus as a model system, further define the

157 erve as mRNA for the envelope protein and in Rous sarcoma virus as src mRNA.

158 polyprotein are intrinsic components of the Rous sarcoma virus assembly pathway.

159 that allowed for the first-time formation of Rous sarcoma virus CA into structures resembling authent

160 Instead, the Rous sarcoma virus capsid protein contains a single cyst

161 olecular disulfide bond during assembly, the Rous sarcoma virus capsid protein does not.

162 of charged amino acids on the surface of the Rous sarcoma virus capsid protein in the assembly of app

163 ed sequence similarity, the structure of the Rous sarcoma virus capsid protein is similar to the stru

164 ences that exist in the C-terminal domain of Rous sarcoma virus capsid relative to the other capsid p

165 on of baby hamster kidney fibroblasts by the Rous sarcoma virus causes a significant increase in the

166 Since codon composition values for Rous sarcoma virus distinguished a "foreign" gene from t

167 We have examined mutant Rous sarcoma virus envelope proteins with truncations or

168 unodeficiency virus type 1, visna virus, and Rous sarcoma virus exhibited different target site prefe

169 o- deficiency virus type 1, visna virus, and Rous sarcoma virus exhibited distinct preferences for wa

170 here that while deletion of the NC domain of Rous sarcoma virus Gag abolishes formation and budding o

171 Using purified Rous sarcoma virus Gag and Gag truncations, we studied t

172 icles (VLPs), we observed that expression of Rous sarcoma virus Gag failed to produce VLPs.

173 The Rous sarcoma virus gag gene contains a cis-acting negati

174 ture of the CA domains in immature assembled Rous sarcoma virus Gag particles.

175 In the context of the Rous sarcoma virus Gag polyprotein, only the nucleocapsi

176 It was shown previously that a Rous sarcoma virus Gag protein missing only the protease

177 The Rous sarcoma virus Gag protein undergoes transient nucle

178 purified, slightly truncated version of the Rous sarcoma virus Gag protein, Delta MBD Delta PR, and

179 rescence correlation spectroscopy-to examine Rous sarcoma virus Gag-Gag and -membrane interactions in

180 gion, Mpsi, from the 5' leader region of the Rous sarcoma virus genome that is sufficient to direct t

181 ckaging signal, MPsi, from the 5' end of the Rous sarcoma virus genome.

182 0 amino acid residue capsid protein from the Rous sarcoma virus has been determined by NMR methods.

183 structure of the three-domain integrase from Rous sarcoma virus in complex with viral and target DNAs

184 contrast, CEF cultures heavily infected with Rous sarcoma virus in the same medium underwent pervasiv

185 plasmid acceptor, purified bacterium-derived Rous sarcoma virus integrase (IN), and a host cell DNA-b

186 ogous positions in visna virus integrase and Rous sarcoma virus integrase changed the target site pre

187 ous studies revealed that truncated forms of Rous sarcoma virus integrase containing two of the three

188 A direct comparison demonstrates that Rous sarcoma virus is capable of infecting aphidicolin-a

189 ct of the retroviral M domain from the avian Rous sarcoma virus is defined and its solution structure

190 Examination of the genomes of three Rous sarcoma virus isolates indicated that codon composi

191 Although the integrity of the entire Rous sarcoma virus leader sequence is important for retr

192 binding chicken Y-box protein that promotes Rous sarcoma virus long terminal repeat (RSV LTR)-driven

193 ilar to the levels observed in vivo with the Rous sarcoma virus long terminal repeat constitutive pro

194 tained human factor IX (hFIX) cDNA driven by Rous sarcoma virus long terminal repeat in the E1 region

195 antibiotic-resistance gene was driven by the Rous sarcoma virus long terminal repeat or the herpes si

196 2(1) collagen promoters and 10-fold from the Rous sarcoma virus long terminal repeat.

197 ng MyoD under transcriptional control of the Rous sarcoma virus long terminal repeat.

198 To further study the role of the Rous sarcoma virus MA sequence in the viral replication

199 us, all of the functions associated with the Rous sarcoma virus MA sequence must be contained within

200 o -90 confers FGF2/FSK responsiveness on the Rous sarcoma virus minimal promoter.

201 In vivo screening of Rous sarcoma virus mutants was performed with randomly m

202 the site phosphorylated by gamma-PAK in the Rous sarcoma virus nucleocapsid protein NC in vivo and i

203 ngeable late assembly domains carried by the Rous sarcoma virus p2b protein and human immunodeficienc

204 , human immunodeficiency virus type 1 p6, or Rous sarcoma virus p2b.

205 er of cis-acting sequences within the RNA of Rous sarcoma virus play a role in preserving a large poo

206 Rous sarcoma virus pre-mRNA contains an element known as

207 coli lacZ reporter gene under control of the Rous sarcoma virus promoter and mammalian RNA processing

208 cloned into a pMAMneo vector containing the Rous sarcoma virus promoter and the neomycin resistance

209 r carrying the cDNA for C/EBPalpha driven by Rous sarcoma virus promoter elements (AdCEBPalpha) or a

210 which sig-mEndo expression was driven by the Rous sarcoma virus promoter had moderately high serum le

211 ls from the beta-galactosidase gene when the Rous sarcoma virus promoter is used to drive transgene e

212 riptional control of a constitutively active Rous sarcoma virus promoter was regulated identically to

213 endogenously expressing SDF-1/CXCL12 under a Rous sarcoma virus promoter were produced.

214 as an inducible HIV-1 genome controlled by a Rous sarcoma virus promoter with lac operator sequences.

215 porter beta-galactosidase gene driven by the Rous Sarcoma Virus promoter.

216 HIT, and CHO cells using cytomegalovirus or Rous sarcoma virus promoters.

217 The Rous sarcoma virus protease displays a high degree of sp

218 Other substrates such as the Rous sarcoma virus protein NC are phosphorylated by gamm

219 ervative substitutions in this region of the Rous sarcoma virus protein were lethal due to a severe d

220 f a weak src 3'ss is necessary for efficient Rous sarcoma virus replication.

221 Cell transformation by Rous sarcoma virus results in a dramatic change of adhes

222 Rous sarcoma virus RNA contains a negative regulator of

223 Accumulation of unspliced Rous sarcoma virus RNA is facilitated in part by a negat

224 only 2.6-fold less efficiently than genomic Rous sarcoma virus RNA.

225 downstream from the 3'ss of the heterologous Rous sarcoma virus src gene.

226 e 3' splice site in the BPV-1 late pre-mRNA, Rous sarcoma virus src pre-mRNA, human immunodeficiency

227 As also found for other retroviruses, the Rous sarcoma virus structural protein Gag is necessary a

228 he negative regulator of splicing (NRS) from Rous sarcoma virus suppresses viral RNA splicing and is

229 ng (NRS) is a long cis-acting RNA element in Rous sarcoma virus that contributes to unspliced RNA acc

230 a mutant of the viral matrix (MA) protein of Rous sarcoma virus that disrupts viral RNA dimerization.

231 to as antisense, can inhibit replication of Rous sarcoma virus through hybridization to viral RNA.

232 We find that Rous sarcoma virus virions, like the human immunodeficie

233 by his discovery of reverse transcriptase in Rous sarcoma virus virions.

234 By cryoelectron tomography, Rous sarcoma virus VLPs show an organized hexameric latt

235 natural or mutated 5' leader sequences from Rous sarcoma virus were expressed in avian cells in the

236 the cell dramatically reduced the release of Rous sarcoma virus, an avian retrovirus.

237 Tva is the receptor for subgroup A Rous sarcoma virus, and it contains a single LDL-A modul

238 quenced a small segment of the 3' end of the Rous sarcoma virus, just inside the poly(A) tail, at the

239 of four promoters (dihydrofolate reductase, Rous sarcoma virus, long terminal repeat, or cytomegalov

240 In Rous sarcoma virus, previous studies have identified imp

241 from human immunodeficiency virus type 1 or Rous sarcoma virus, respectively.

242 In Rous sarcoma virus, splicing control is achieved in part

243 gate Gag protein structure and processing in Rous sarcoma virus, the prototype of the avian sarcoma a

244 e used cryo-electron tomography to visualize Rous sarcoma virus, the prototypic alpharetrovirus.

245 e-bound nonreceptor tyrosine kinase Src from Rous sarcoma virus, these interactions are mediated by a

246 In HIV-1 and Rous sarcoma virus, this region forms a rod-like structu

247 ses, including the prototypic oncoretrovirus Rous sarcoma virus, were synthesized on cytosolic riboso

248 The discovery of Rous sarcoma virus, which was reported by Peyton Rous in

249 We have constructed and characterized a Rous sarcoma virus-based retroviral vector with the host

250 Using the Rous sarcoma virus-derived vector RCAS, we previously sh

251 is tyrosine-phosphorylated when expressed in Rous sarcoma virus-infected chicken embryo fibroblasts (

252 1 is shown to transcriptionally activate the Rous sarcoma virus-long terminal repeat promoter, which

253 nducible, constitutively expressed reporter, Rous sarcoma virus-luciferase (RSV-LUC); nor does it blo

254 initially identified as a phosphoprotein in Rous sarcoma virus-transformed cells.

255 HT29, and CaCo2) compared with a nonspecific Rous sarcoma virus-yCD virus.

256 domain that is present in the Gag protein of Rous sarcoma virus.

257 dentified in the gag-specific protein p2b of Rous sarcoma virus.

258 homologue of v-src, the transforming gene of Rous Sarcoma virus.

259 ch controls fibroblast transformation by the Rous sarcoma virus.

260 ive regulator of splicing (NRS) element from Rous sarcoma virus.

261 nalyses of two in-vitro-assembled capsids of Rous sarcoma virus.

262 that of the naturally nonmyristoylated MA of Rous sarcoma virus.

263 1) and 2, simian immunodeficiency virus, and Rous sarcoma virus.